|Mr. SÃ©bastien Peltier||Co-Founder, Chairman & CEO||N/A||N/A||1978|
|Mr. Jocelyn Pineau||Co-Founder, CFO & Director||N/A||N/A||N/A|
|Mr. Sebastien Bessy||Chief Operating Marketing & Bus. Officer and Director||N/A||N/A||N/A|
|Mr. Pascal Sirvent Ph.D.||CSO & Director||N/A||N/A||N/A|
|Ms. Murielle Cazaubiel||CMO & Director||N/A||N/A||N/A|
|Dr. Josep Infesta||Head of Global Bus. Devel.||N/A||N/A||N/A|
|Ms. AgnÃ¨s Tixier||Exec. Director of Credit Mutuel & Equity SCR and Member of Supervisory Board||N/A||N/A||1969|
|Mr. Philippe Sibour||Chief Exec. Officer of Alliance Consulting||N/A||N/A||N/A|
Valbiotis SA engages in the research and development of health nutrition products to prevent metabolic diseases in response to unmet medical needs. The company develops TOTUM-63 for the treatment of type 2 diabetes; TOTUM-070 for hypercholesterolemia; TOTUM-448 for the treatment of patient with non-alcoholic fatty liver disease; and TOTUM-854 for arterial hypertension. It has a strategic partnership with NestlÃ© Health Science. The company was founded in 2014 and is headquartered in PÃ©rigny, France.
Valbiotis SA’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.